123 related articles for article (PubMed ID: 19625343)
1. N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
Tan WW; Hillman DW; Salim M; Northfelt DW; Anderson DM; Stella PJ; Niedringhaus R; Bernath AM; Gamini SS; Palmieri F; Perez EA
Ann Oncol; 2010 Mar; 21(3):493-497. PubMed ID: 19625343
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Lordick F; von Schilling C; Bernhard H; Hennig M; Bredenkamp R; Peschel C
Br J Cancer; 2003 Aug; 89(4):630-3. PubMed ID: 12915869
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.
Perez EA; Hillman DW; Mailliard JA; Ingle JN; Ryan JM; Fitch TR; Rowland KM; Kardinal CG; Krook JE; Kugler JW; Dakhil SR
J Clin Oncol; 2004 Jul; 22(14):2849-55. PubMed ID: 15254052
[TBL] [Abstract][Full Text] [Related]
4. N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.
Crozier JA; Advani PP; LaPlant B; Hobday T; Jaslowski AJ; Moreno-Aspitia A; Perez EA
Clin Breast Cancer; 2016 Feb; 16(1):23-30. PubMed ID: 26381420
[TBL] [Abstract][Full Text] [Related]
5. Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens.
Shigeoka Y; Itoh K; Igarashi T; Ishizawa K; Saeki T; Fujii H; Minami H; Imoto S; Sasaki Y
Jpn J Clin Oncol; 2001 Aug; 31(8):370-4. PubMed ID: 11574629
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
Reni M; Panucci MG; Passoni P; Bonetto E; Nicoletti R; Ronzoni M; Zerbi A; Staudacher C; Di Carlo V; Villa E
Cancer Invest; 2004; 22(5):688-96. PubMed ID: 15581049
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
Argiris A; Buchanan A; Brockstein B; Kolesar J; Ghebremichael M; Pins M; Hahn K; Axelrod R; Forastiere A
Cancer; 2009 Oct; 115(19):4504-13. PubMed ID: 19634157
[TBL] [Abstract][Full Text] [Related]
8. Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Kucukzeybek Y; Dirican A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Medeni M; Tarhan MO
Asian Pac J Cancer Prev; 2012; 13(6):2771-4. PubMed ID: 22938457
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Ushijima K; Kamura T; Tamura K; Kuzuya K; Sugiyama T; Noda K; Ochiai K
Int J Clin Oncol; 2013 Feb; 18(1):126-31. PubMed ID: 22127346
[TBL] [Abstract][Full Text] [Related]
10. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Earle CC; Kulke MH; Meyerhardt JA; Blaszkowsky LS; Zhu AX; Fidias P; Vincitore MM; Mayer RJ; Fuchs CS
Ann Oncol; 2009 Mar; 20(3):475-80. PubMed ID: 19139178
[TBL] [Abstract][Full Text] [Related]
11. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma.
Park SR; Chun JH; Yu MS; Lee JH; Ryu KW; Choi IJ; Kim CG; Lee JS; Kim YW; Bae JM; Kim HK
Br J Cancer; 2006 May; 94(10):1402-6. PubMed ID: 16641896
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.
Burtness B; Gibson M; Egleston B; Mehra R; Thomas L; Sipples R; Quintanilla M; Lacy J; Watkins S; Murren JR; Forastiere AA
Ann Oncol; 2009 Jul; 20(7):1242-8. PubMed ID: 19429872
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
Raff JP; Rajdev L; Malik U; Novik Y; Manalo JM; Negassa A; Hopkins U; Sarta C; Sparano JA
Clin Breast Cancer; 2004 Feb; 4(6):420-7. PubMed ID: 15023243
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
Chitapanarux I; Tonusin A; Sukthomya V; Charuchinda C; Pukanhapan N; Lorvidhaya V
Gynecol Oncol; 2003 Jun; 89(3):402-7. PubMed ID: 12798702
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study.
Burtness B; Powell M; Catalano P; Berlin J; Liles DK; Chapman AE; Mitchell E; Benson AB
Am J Clin Oncol; 2016 Aug; 39(4):340-5. PubMed ID: 24685886
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
Jatoi A; Tirona MT; Cha SS; Alberts SR; Rowland KM; Morton RF; Nair S; Kardinal CG; Stella PJ; Mailliard JA; Sargen D; Goldberg RM
Int J Gastrointest Cancer; 2002; 32(2-3):115-23. PubMed ID: 12794247
[TBL] [Abstract][Full Text] [Related]
18. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA
Cancer Invest; 2008 Feb; 26(1):47-52. PubMed ID: 18181045
[TBL] [Abstract][Full Text] [Related]
19. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
20. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
